ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
INVESTORS
[동아사이언스] [재생의료 최전선]② 기적의 항암제 ‘CAR-T’ 한계 극복 도전하는 토종기업
2025/05/30
[재생의료 최전선]② 기적의 항암제 ‘CAR-T’ 한계 극복 도전하는 토종기업 : 동아사이언스
Prev
[비즈월드] [국내 CAR-T 선두 큐로셀 ②] “‘림카토’ 넘어 더 다양한 암종 정복으로”
Next
큐로셀, BIO USA 2025 기업 발표자로 선정…글로벌 파트너십 본격 확대
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.